BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment
(2019)
Journal Article
Malignant mesothelioma (MMe) is a cancer with poor prognosis and resistance to standard treatments. Recent reports have highlighted the role of the BRCA associated protein 1 gene BAP1 in the development of MMe. In this study, the chemosensitivity of... Read More about BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment.